Cargando…
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure
Autores principales: | Masotti, Luca, Cioni, Elisa, Grifoni, Elisa, Cei, Francesco, Tarquini, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167827/ https://www.ncbi.nlm.nih.gov/pubmed/35680497 http://dx.doi.org/10.1016/j.ejim.2022.06.004 |
Ejemplares similares
-
Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study
por: Masotti, Luca, et al.
Publicado: (2022) -
Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia
por: Masotti, Luca, et al.
Publicado: (2022) -
Interleukin-6 as prognosticator in patients with COVID-19
por: Grifoni, Elisa, et al.
Publicado: (2020) -
Expanded Multiple Organ Dysfunction score: is it better than the Sequential Organ Failure Syndrome score?
por: Haddad, Z, et al.
Publicado: (2006) -
Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure
por: Aoki, Tatsuya, et al.
Publicado: (2017)